Answers are grounded in this paper and cite their sources.
Foundation model integrates DNA methylation data to improve precision medicine applications, highlighting its utility across various tasks.
DNA methylation regulates gene expression, differentiation, and disease, making it a key target for computational modeling in precision medicine. To integrate high-resolution whole-genome bisulfite sequencing (WGBS) data into a unified analytical framework, we developed MethylFM, a transformer-based foundation model that captures context-aware methylation patterns and supports multiple downstream tasks.We trained on the BLUEprint Epigenome dataset, comprising single-base WGBS profiles across diverse blood cell types with matched histone modification and transcriptome data. By focusing on ±100 CpG sites around transcription start sites (TSS), MethylFM targets regulatory regions central to gene expression and chromatin dynamics. Built on a BERT-style transformer with rotary positional embeddings and a masked-value prediction objective, it learns robust representations capturing both local and long-range dependencies in methylation.MethylFM demonstrated versatility across three downstream applications. For CpG-level imputation, it reconstructed high-resolution WGBS profiles from 450k array data with strong accuracy (R2 > 0.6, MAE < 0.15). When benchmarked against METHimpute, evaluation was restricted to two samples due to METHimpute’s intensive runtime; nonetheless, MethylFM achieved slightly higher accuracy (R2 = 0.518 vs. 0.513), underscoring both precision and computational efficiency. In TSS-level H3K27ac prediction, the model reached R2 = 0.614, matching the state-of-the-art M2A (R2 = 0.617) and highlighting its capacity to infer promoter activity directly from DNA methylation. Finally, sample-level clustering based on predicted H3K27ac profiles accurately recapitulated hematopoietic lineages, surpassing experimental H3K27ac data (Silhouette = 0.47 vs. 0.30) and approaching RNA-seq-derived clustering performance (Silhouette = 0.51), demonstrating that MethylFM captures biologically meaningful epigenetic structure. Together, these results establish MethylFM as a generalizable and efficient framework for epigenomic modeling, enabling cost-effective methylation imputation, promoter activity prediction, and cellular identity characterization to advance biomarker discovery and precision medicine. Citation Format: Limeng Pu, Xiang Chen, . MethylFM: A DNA methylation foundation model for modeling epigenomic regulatory dynamics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5482.
No takes yet. Share an insight, caveat, or question.
Pu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: